Development asset linked to Vir Biotechnology in public FDA and regional records. Molecular target: Spike glycoprotein.
- Target
- Spike glycoprotein
- Mechanism
- Spike glycoprotein inhibitor
biotech · Chronic Hepatitis D Virus (HDV) Infection · Chronic Hepatitis B · VIR
Vir Biotechnology
Vir Biotechnology drug portfolio — 17 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
1800 Owens St, Suite 900, San Francisco, California 94158, US HQ
2016 Founded
479 Employees
Public company Type
VIR · NYSE Ticker
Company details
- Status
- Public
- HQ
- 1800 Owens St, Suite 900, San Francisco, California 94158, US
- Founded
- 2016
- Employees
- 479
- Programs
- 34
- Drugs
- 17
- Patents
- 6
Vir Biotechnology pipeline
Portfolio lens on 17 drugs and development assets — regulatory status, targets, and deep links to NovaPharmaNews drug profiles.
Vir Biotechnology drug portfolio — 17 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Drug portfolio
-
-
bulevirtide
Antiinfectives for systemic use (J05)Antiinfectives for systemic use (J05) compound in Vir Biotechnology's portfolio. Mechanism: Bile acid transporter inhibitor.
- Mechanism
- Bile acid transporter inhibitor
-
covid-19 vaccine (inactivated, adjuvanted, adsorbed)
Antiinfectives for systemic use (J07)Antiinfectives for systemic use (J07) compound in Vir Biotechnology's portfolio. Mechanism: Biological vaccine - induces immune response.
- Mechanism
- Biological vaccine - induces immune response
-
dolutegravir
Antiinfectives for systemic use (J05)US regulatory status: approved.
-
influenza vaccine (live attenuated, nasal)
Antiinfectives for systemic use (J07)Antiinfectives for systemic use (J07) compound in Vir Biotechnology's portfolio.
-
Development asset linked to Vir Biotechnology in public FDA and regional records.
-
peginterferon alfa-2a
Antineoplastic and immunomodulating agents (L03)US regulatory status: approved. Molecular target: Interferon alpha/beta receptor.
- Target
- Interferon alpha/beta receptor
- Mechanism
- Interferon alpha/beta receptor agonist
-
pembrolizumab
Antineoplastic and immunomodulating agents (L01)US regulatory status: approved. Molecular target: Programmed cell death protein 1.
- Target
- Programmed cell death protein 1
- Mechanism
- Programmed cell death protein 1 inhibitor
-
Development asset linked to Vir Biotechnology in public FDA and regional records.
-
Development asset linked to Vir Biotechnology in public FDA and regional records.
-
sotrovimab
Antiinfectives for systemic use (J06)Antiinfectives for systemic use (J06) compound in Vir Biotechnology's portfolio. Molecular target: Spike glycoprotein.
- Target
- Spike glycoprotein
- Mechanism
- Spike glycoprotein inhibitor
-
Development asset linked to Vir Biotechnology in public FDA and regional records.
-
Development asset linked to Vir Biotechnology in public FDA and regional records.
-
US regulatory status: approved. Molecular target: Human immunodeficiency virus type 1 reverse transcriptase.
- Target
- Human immunodeficiency virus type 1 reverse transcriptase
- Mechanism
- Human immunodeficiency virus type 1 reverse transcriptase inhibitor
-
tenofovir disoproxil
Antiinfectives for systemic use (J05)Antiinfectives for systemic use (J05) compound in Vir Biotechnology's portfolio.
-
US regulatory status: approved. Molecular target: Human immunodeficiency virus type 1 reverse transcriptase.
- Target
- Human immunodeficiency virus type 1 reverse transcriptase
- Mechanism
- Human immunodeficiency virus type 1 reverse transcriptase inhibitor
-
Development asset linked to Vir Biotechnology in public FDA and regional records.